Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 02, 2022 08:37 ET | Source: Hillstream BioPharma Inc.

Hillstream BioPharma R&D Day Highlights Ferroptosis, the Non-Genetic Novel, Emerging Mechanism of Action, Targeting Drug Resistant and Devastating Cancers

HSB-1216’s active moiety in clinical pilot study produced a 71% response rate in TNBC and epithelial carcinomasHSB-1216 was recently granted Orphan Drug Designation to treat Uveal Melanoma by the...
February 16, 2022 09:40 ET | Source: Hillstream BioPharma Inc.

Hillstream BioPharma Receives Orphan Drug Designation for HSB-1216 for the Treatment of Uveal Melanoma

-Uveal melanoma is an aggressive intraocular malignancy with a poor prognosis in which 50% of patients develop metastatic disease- -Evidence implicates ferroptosis, an emerging iron-mediated cell...